Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Conversion disorder is a psychiatric condition in which a person has neurological symptoms affecting movement or the senses, like paralysis or blindness, with no physiological cause. In the past, such ...

Support detection for WebP and AVIF has been removed from GLTFLoader.